Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
Sponsor: West China Hospital
Summary
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Official title: Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-04-05
Completion Date
2025-05-05
Last Updated
2025-04-30
Healthy Volunteers
No
Interventions
postoperative adjuvant therapy
Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
Locations (1)
West China Hospital
Chengdu, Sichuan, China